EFTReFFECTOR TherapeuticsEFTR info
$1.30info-0.76%24h
Global rank35564
Market cap$3.89M
Change 7d-
YTD Performance-89.01%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    eFFECTOR Therapeutics (EFTR) Stock Overview

    eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

    EFTR Stock Information

    Symbol
    EFTR
    Address
    142 North Cedros AvenueSolana Beach, CA 92075United States
    Founded
    -
    Trading hours
    -
    Website
    https://effector.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    858 925 8215

    eFFECTOR Therapeutics (EFTR) Price Chart

    -
    Value:-

    eFFECTOR Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.30
    N/A
    Market Cap
    $3.89M
    N/A
    Shares Outstanding
    3.00M
    N/A
    Employees
    15.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org